Literature DB >> 4542702

Letter: Experimental model for von Willebrand's disease.

D Meyer, C S Jenkins, M Dreyfus, M J Larrieu.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4542702     DOI: 10.1038/243293a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  7 in total

1.  [Willebrand's disease and platelet adhesiveness in the presence of ristocetine].

Authors:  P Alexander; F Streiff; J F Stoltz; E Andre
Journal:  Blut       Date:  1975-08

2.  Platelet membrane glycoproteins implicated in ristocetin-induced aggregation. Studies of the proteins on platelets from patients with Bernard-Soulier syndrome and von Willebrand's disease.

Authors:  C S Jenkins; D R Phillips; K J Clemetson; D Meyer; M J Larrieu; E F Lüscher
Journal:  J Clin Invest       Date:  1976-01       Impact factor: 14.808

3.  Studies on human antihemophilic factor. Evidence for a covalently linked subunit structure.

Authors:  M E Switzer; P A McKee
Journal:  J Clin Invest       Date:  1976-04       Impact factor: 14.808

4.  Defective ristocetin and bovine factor VIII-induced platelet aggregation in normal rats.

Authors:  G de Gaetano; M B Donati; I Reyers-Degli Innocenti; M C Roncaglioni
Journal:  Experientia       Date:  1975-04-15

Review 5.  Platelets, thrombosis and drugs.

Authors:  J F Mustard; M A Packham
Journal:  Drugs       Date:  1975       Impact factor: 9.546

6.  Survival of 125iodine-labeled Factor VIII in normals and patients with classic hemophilia. Observations on the heterogeneity of human Factor VIII.

Authors:  J Over; J J Sixma; M H Bruïne; M C Trieschnigg; R A Vlooswijk; N H Beeser-Visser; B N Bouma
Journal:  J Clin Invest       Date:  1978-08       Impact factor: 14.808

7.  Factor VIII coagulant activity and factor VIII-like antigen: independent molecular entities.

Authors:  T S Zimmerman; T S Edgington
Journal:  J Exp Med       Date:  1973-10-01       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.